Massachusetts has selected Impruvon's Electronic Medication Administration Record (eMAR) platform as its statewide solution for medication management across healthcare settings. The platform has achieved full compliance with the Commonwealth's Medication Administration Program standards. The state-funded system is now available at no cost to all MAP providers, covering software access, training, and support. The platform was developed through collaboration with the Massachusetts Executive Office of Health and Human Services and constituent agencies including the Department of Public Health, Department of Mental Health, and Department of Developmental Services. Impruvon specialises in medication management technology for intellectual and developmental disabilities, behavioural health, and home and community-based services settings. The company aims to reduce medication errors and administrative burden whilst improving health outcomes.

In addition, Scene Health is collaborating with another small business, Impruvon Health, to develop the novel electronic adherence monitor that will be used in this study.

In line with Maryland’s industry trends, one of the state’s leading technology sectors landed its primary city’s biggest venture capital deals last quarter. Following a languid Q3, Baltimore saw $158.1 million in venture capital funding across 13 deals in 2024’s final three months, according to the latest quarterly Venture Monitor report from PitchBook and the National Venture Capital Association. By comparison, the late summer and early fall comprised $69.2 million in funding across 10 deals. It’s not the highest valuation of 2024 — the year’s second quarter saw $359.4 million across 14 deals, and a much lower $89.7 across 19 deals in Q1. The last quarter of 2023 was even more sluggish at a mere $45.8 million through 22 deals, meaning the transactions were more frequent and lower in valuation.  E-commerce firm SamCart, whose website lists offices in Fulton, Maryland and Austin, Texas, brought in half of the most recent quarter’s venture funds, trailed by other largely later-stage companies. This company stage trend reflects VC dynamics throughout the country. Funders still look for more mature companies in which to invest, per Mike Ravenscroft, the managing director of the University System of Maryland Momentum Fund. That was the case for most of 2023 and 2024, so he doesn’t find this continuation surprising.The uptick in cash is promising, but nowhere near as robust as 2021’s highs, he explained. Caution is still the name of the game.Mike Ravenscroft“I do not think that the average startup is, or should be, throwing caution to the wind,” Ravenscroft told Technical.ly, “and thinking that the environment is picked up and that everything’s turned around.”Raising at the seed stage remains a challenge, he said. Venture firms, many of which are struggling to raise money themselves, now look to companies with a high return potential and little risk. In some ways, this sobering reality for early-stage companies can be positive, Ravenscroft said. “The shortage of funding has compelled founders to be a lot more precise and measured in the growth targets that they’re projecting,” he said